SONOMA PHARMACEUTICALS INC (SNOA)

US83558L2043 - Common Stock

2.63  +0.08 (+3.14%)

Fundamental Rating

2

SNOA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. The financial health of SNOA is average, but there are quite some concerns on its profitability. SNOA does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SNOA has reported negative net income.
SNOA had a negative operating cash flow in the past year.
In the past 5 years SNOA always reported negative net income.
SNOA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

SNOA has a Return On Assets (-26.93%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -68.87%, SNOA is in line with its industry, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
ROA -26.93%
ROE -68.87%
ROIC N/A
ROA(3y)-30.51%
ROA(5y)-28.12%
ROE(3y)-67.28%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

SNOA's Gross Margin of 38.52% is in line compared to the rest of the industry. SNOA outperforms 58.64% of its industry peers.
In the last couple of years the Gross Margin of SNOA has declined.
SNOA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5Y-4.46%

More info and screens

4

2. Health

2.1 Basic Checks

SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNOA has been reduced compared to 1 year ago.
SNOA has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNOA has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -19.06, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
SNOA has a worse Altman-Z score (-19.06) than 84.82% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that SNOA is not too dependend on debt financing.
SNOA has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -19.06
ROIC/WACCN/A
WACC9.5%

2.3 Liquidity

SNOA has a Current Ratio of 3.69. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
SNOA has a Current ratio (3.69) which is in line with its industry peers.
SNOA has a Quick Ratio of 2.84. This indicates that SNOA is financially healthy and has no problem in meeting its short term obligations.
SNOA has a Quick ratio (2.84) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 2.84

More info and screens

3

3. Growth

3.1 Past

SNOA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -225.32%.
The Revenue has grown by 11.87% in the past year. This is quite good.
Measured over the past years, SNOA shows a decrease in Revenue. The Revenue has been decreasing by -7.66% on average per year.
EPS 1Y (TTM)-225.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.83%
Revenue 1Y (TTM)11.87%
Revenue growth 3Y-11.91%
Revenue growth 5Y-7.66%
Sales Q2Q%31.05%

3.2 Future

The Earnings Per Share is expected to decrease by -41.70% on average over the next years. This is quite bad
The Revenue is expected to grow by 15.09% on average over the next years. This is quite good.
EPS Next Y24.72%
EPS Next 2Y-41.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year5.59%
Revenue Next 2Y15.09%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNOA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SNOA's earnings are expected to decrease with -41.70% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.7%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNOA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONOMA PHARMACEUTICALS INC

NASDAQ:SNOA (12/20/2024, 8:00:02 PM)

2.63

+0.08 (+3.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-06 2025-02-06/amc
Inst Owners1.64%
Inst Owner Change-87.88%
Ins Owners1.58%
Ins Owner Change0%
Market Cap3.52M
Analysts85.71
Price Target17.34 (559.32%)
Short Float %3.06%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.89%
Min EPS beat(2)-14.38%
Max EPS beat(2)42.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.74%
Min Revenue beat(2)-15.63%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-15.24%
Min Revenue beat(4)-18.17%
Max Revenue beat(4)-11.85%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.33%
PT rev (3m)1033.33%
EPS NQ rev (1m)13.75%
EPS NQ rev (3m)-527.27%
EPS NY rev (1m)83.25%
EPS NY rev (3m)83.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.74%
Revenue NY rev (1m)-8.9%
Revenue NY rev (3m)-8.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-4.91
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS10.11
BVpS3.99
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.93%
ROE -68.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.52%
FCFM N/A
ROA(3y)-30.51%
ROA(5y)-28.12%
ROE(3y)-67.28%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.79%
GM growth 5Y-4.46%
F-Score6
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.5%
Cap/Sales 0.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 2.84
Altman-Z -19.06
F-Score6
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)97.01%
Cap/Depr(5y)87.41%
Cap/Sales(3y)1.09%
Cap/Sales(5y)1.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-225.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.83%
EPS Next Y24.72%
EPS Next 2Y-41.7%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.87%
Revenue growth 3Y-11.91%
Revenue growth 5Y-7.66%
Sales Q2Q%31.05%
Revenue Next Year5.59%
Revenue Next 2Y15.09%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.35%
OCF growth 3YN/A
OCF growth 5YN/A